Alnylam Pharmaceuticals, Inc.ALNYNASDAQ
Loading
PB Ratio: Premium ValuationElevated
Percentile Rank93
5Y CAGR+35.0%
Year-over-Year Change
Price-to-book ratio
5Y CAGR
+35.0%/yr
Long-term compound
Percentile
P93
Near historical high
vs 5Y Ago
4.5x
Strong expansion
Streak
1 yr
Consecutive declineElevated
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 66.01 | -85.3% |
| 2024 | 447.73 | +513.2% |
| 2023 | -108.36 | +40.7% |
| 2022 | -182.78 | -635.2% |
| 2021 | 34.15 | +132.2% |
| 2020 | 14.71 | +68.1% |
| 2019 | 8.75 | +55.3% |
| 2018 | 5.63 | -13.5% |
| 2017 | 6.51 | +87.0% |
| 2016 | 3.48 | - |